For patients with mild‐to‐moderate COVID‐19, pramipramide has been shown to decrease ACE2 and TMPRSS2 expression in lung cancer cells, prevent SARS‐CoV‐2 from entering host cells, and facilitate faster virus clearance [66]. Here, TMPRSS2 is linked to COVID-19.